DE69918716D1 - Triazinoneverbindungen für die behhandlung von krankheiten verursacht durch neospora und toxoplasma - Google Patents

Triazinoneverbindungen für die behhandlung von krankheiten verursacht durch neospora und toxoplasma

Info

Publication number
DE69918716D1
DE69918716D1 DE69918716T DE69918716T DE69918716D1 DE 69918716 D1 DE69918716 D1 DE 69918716D1 DE 69918716 T DE69918716 T DE 69918716T DE 69918716 T DE69918716 T DE 69918716T DE 69918716 D1 DE69918716 D1 DE 69918716D1
Authority
DE
Germany
Prior art keywords
neospora
toxoplasma
treatment
diseases caused
triazinone compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918716T
Other languages
English (en)
Other versions
DE69918716T2 (de
Inventor
J Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of DE69918716D1 publication Critical patent/DE69918716D1/de
Publication of DE69918716T2 publication Critical patent/DE69918716T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69918716T 1998-12-22 1999-12-18 Triazinoneverbindungen für die behhandlung von krankheiten verursacht durch neospora und toxoplasma Expired - Lifetime DE69918716T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US218713 1998-12-22
US09/218,713 US6194408B1 (en) 1998-12-22 1998-12-22 Triazineone compounds for treating diseases due to Sarcocystis, Neospora and Toxoplasma
PCT/US1999/030293 WO2000037064A2 (en) 1998-12-22 1999-12-18 Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma

Publications (2)

Publication Number Publication Date
DE69918716D1 true DE69918716D1 (de) 2004-08-19
DE69918716T2 DE69918716T2 (de) 2005-08-04

Family

ID=22816196

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918716T Expired - Lifetime DE69918716T2 (de) 1998-12-22 1999-12-18 Triazinoneverbindungen für die behhandlung von krankheiten verursacht durch neospora und toxoplasma

Country Status (17)

Country Link
US (1) US6194408B1 (de)
EP (1) EP1140102B1 (de)
JP (1) JP4806121B2 (de)
KR (1) KR100661102B1 (de)
CN (1) CN1188128C (de)
AT (1) ATE270891T1 (de)
AU (1) AU770108B2 (de)
BR (1) BR9916432A (de)
CA (1) CA2356151C (de)
DE (1) DE69918716T2 (de)
ES (1) ES2226492T3 (de)
HK (1) HK1043315A1 (de)
HU (1) HU228994B1 (de)
NZ (1) NZ512478A (de)
PT (1) PT1140102E (de)
WO (1) WO2000037064A2 (de)
ZA (1) ZA200104205B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469987B1 (en) 1998-01-13 2002-10-22 Enterasys Networks, Inc. Virtual local area network with trunk stations
WO2000019964A2 (en) 1998-10-08 2000-04-13 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
DE19958388A1 (de) * 1999-12-03 2001-06-07 Bayer Ag Triazinonverbindungen zur Behandlung von durch den Befall mit parasitischen Protozoen bedingten Krankheiten
CA2407517A1 (en) * 2000-04-25 2001-11-01 Wyeth Equine protozoal myeloencephalitis vaccine
DE10040110A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfoxiden zur Bekämpfung von Coccidiosen
US6562007B1 (en) * 2000-09-28 2003-05-13 Bayer Healthcare Llc Adjustable dosage syringe
US20060240049A1 (en) * 2003-01-16 2006-10-26 Bart De Spiegeleer Anti-protozoal compositions comprising diclazuril
DE102007025908A1 (de) * 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
DE102009012423A1 (de) * 2009-03-10 2010-09-16 Bayer Animal Health Gmbh Zubereitung auf Ölbasis
KR101148098B1 (ko) * 2010-04-30 2012-05-22 한국화학연구원 1-［4-（4-니트로-페녹시）-페닐］-프로판-1-온을 유효성분으로 함유하는 톡소포자충 및 콕시디움에 기인한 질환의 예방 및 치료용 조성물
KR101242535B1 (ko) * 2010-10-05 2013-03-12 주식회사이-글벳 콕시듐 치료 및 예방을 위한 조성물의 제조방법
CN102772363B (zh) * 2012-08-22 2013-10-09 青岛康地恩药业股份有限公司 一种含泊那珠利的溶液剂及其制备方法
WO2018031935A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
EP3720844A4 (de) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation Arzneimittelzusammensetzungen
WO2020093014A1 (en) * 2018-11-02 2020-05-07 Adamis Pharmaceuticals Corporation Drug compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2313721A1 (de) * 1973-03-20 1974-10-03 Bayer Ag Neue 1-phenylsubstituierte 1,3,5triazine, verfahren zu ihrer herstellung, sowie ihre verwendung als arzneimittel
AU616916B2 (en) 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
DE3826058A1 (de) 1988-07-30 1990-02-08 Bayer Ag Mittel gegen fischparasiten
US4933341A (en) * 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
US5196562A (en) 1988-10-08 1993-03-23 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
EP0377903A3 (de) 1989-01-09 1991-07-17 Bayer Ag Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung
CN1044905A (zh) 1989-02-16 1990-08-29 赫彻斯特股份公司 鱼和昆虫寄生虫对抗剂
DE4030042A1 (de) 1990-05-17 1991-11-21 Bayer Ag Verwendung von substituierten 1,2,4-triazindionen
DE4120138A1 (de) 1991-06-19 1992-12-24 Bayer Ag Substituierte hexahydro-1,2,4-triazindione, verfahren zu ihrer herstellung, zwischenprodukte dafuer und ihre verwendung
US5883095A (en) * 1997-08-07 1999-03-16 University Of Kentucky Research Foundation Formulations and methods to treat and prevent equine protozoal myeloencephalitis
BR9808114A (pt) * 1997-03-31 2000-03-08 David Granstrom Formulação de ração para cavalos utilizável para tratar epm, processos para tratar pm em um cavalo que necessita deste tratamento, para prevenir infecção com s. neutrona em cavalos, e, para exterminar s. neurona em cavalos
US5830893A (en) * 1997-04-23 1998-11-03 Mortar & Pestle Veterinary Pharmacy, Inc. Treatment of equine protozoan myeloencephalitis using triazinediones

Also Published As

Publication number Publication date
JP4806121B2 (ja) 2011-11-02
KR20010087412A (ko) 2001-09-15
EP1140102B1 (de) 2004-07-14
JP2002532545A (ja) 2002-10-02
CN1331594A (zh) 2002-01-16
HUP0104710A3 (en) 2003-10-28
HK1043315A1 (en) 2002-09-13
CA2356151A1 (en) 2000-06-29
CA2356151C (en) 2009-02-24
WO2000037064A2 (en) 2000-06-29
DE69918716T2 (de) 2005-08-04
EP1140102A2 (de) 2001-10-10
HU228994B1 (en) 2013-07-29
NZ512478A (en) 2003-07-25
ATE270891T1 (de) 2004-07-15
AU2370900A (en) 2000-07-12
HUP0104710A2 (hu) 2002-04-29
PT1140102E (pt) 2004-10-29
AU770108B2 (en) 2004-02-12
WO2000037064A3 (en) 2000-10-26
CN1188128C (zh) 2005-02-09
BR9916432A (pt) 2001-09-04
KR100661102B1 (ko) 2006-12-26
US6194408B1 (en) 2001-02-27
ES2226492T3 (es) 2005-03-16
ZA200104205B (en) 2002-05-22

Similar Documents

Publication Publication Date Title
ATE270891T1 (de) Triazinoneverbindungen für die behhandlung von krankheiten verursacht durch neospora und toxoplasma
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
NO990912D0 (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse
DE60036456D1 (de) Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid
MY119375A (en) Treatment of tinnitus using neuroprotective agents
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
GB0130677D0 (en) Medicaments and novel compounds
BR9808221A (pt) Método de tratamento de tumor.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ATE125704T1 (de) Behandlung neurodegenerativer erkrankungen.
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
BR9916417A (pt) Compostos triazinaona para tratamento de doenças devidas à sarcosystis, neospora e toxoplasma
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
PT1056458E (pt) Tratamento de dor cronica
DE60115237D1 (de) Praziquantel zusammensetzungen zur behandlung von krankheiten verursacht durch kokzidien
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
EA200200846A1 (ru) Соединения, полезные для лечения или предупреждения заболеваний, опосредуемых альфа-2в-адреноцептором
EA200101043A1 (ru) Способ лечения неврологических или нейропсихиатрических расстройств

Legal Events

Date Code Title Description
8364 No opposition during term of opposition